Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia:reports from the 56th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2015.03.002
- VernacularTitle:骨髓增生异常综合征和再生障碍性贫血患者异基因造血干细胞移植的时机选择:第56届美国血液学会年会报道
- Author:
Xudong TANG
;
Lu ZHANG
;
Feng LIU
- Publication Type:Journal Article
- Keywords:
Myelodysplastic syndromes;
Aplastic anemia;
Allogeneic stem cell transplantation;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2015;24(3):132-134
- CountryChina
- Language:Chinese
-
Abstract:
New progresses of timing of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndrome (MDS) and aplastic anemia in the 56th ASH annual meetings were reviewed.Allo-HSCT for MDS was a potentially curative procedure,but it was associated with a significant risk of morbidity and mortality.With the recent approval of disease-modifying agents,the appropriate timing of alloHSCT needed to be addressed.For low and intermediate-1 IPSS risk groups,the decision to delay HSCT from the time of diagnosis maximized overall survival.For patients with intermediate-2 and high-risk disease,immediate HSCT at the time of diagnosis was associated with a greater number of life-years than HSCT at a delayed time point.The methods that underwent HSCT were after azacitidine,leukemia-type induction chemotherapy,or both.for severe aplastic anemia (SAA),HSCT was a proven cure,but HLA-matched sibling donors were found in fewer than 25 ％ of newly diagnosed patients.The use of early unrelated donor HSCT was an evolving concept that will became more accepted as improvements in HSCT outcomes continued.Moving forward,HLA-matched related and unrelated donor HSCT will likely become the treatment of choice for most patients with higher-risk MDS and newly diagnosed SAA.
